Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Prevention |
RCV000721617 | SCV000852718 | uncertain significance | not provided | 2018-09-10 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000800253 | SCV000939954 | pathogenic | RYR1-related disorder | 2023-01-22 | criteria provided, single submitter | clinical testing | This missense change has been observed in individual(s) with clinical features of autosomal dominant congenital myopathy (PMID: 25214167; Invitae). In at least one individual the variant was observed to be de novo. For these reasons, this variant has been classified as Pathogenic. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt RYR1 protein function. ClinVar contains an entry for this variant (Variation ID: 590572). This variant is present in population databases (rs772003357, gnomAD 0.005%). This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 2195 of the RYR1 protein (p.Pro2195Leu). |
Gene |
RCV000721617 | SCV002102649 | pathogenic | not provided | 2024-09-18 | criteria provided, single submitter | clinical testing | Reported as heterozygous in an individual with congenital myopathy, but familial segregation information was not provided (PMID: 25214167); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 12668474, 25214167, 32236737) |
Institute of Human Genetics, |
RCV000721617 | SCV002496422 | uncertain significance | not provided | 2022-03-24 | criteria provided, single submitter | clinical testing | PP3, PP5 |
Revvity Omics, |
RCV000721617 | SCV003813092 | uncertain significance | not provided | 2019-12-01 | criteria provided, single submitter | clinical testing |